Biogen shares rise after Q1 earnings beat, growth-product momentum, and pipeline/M&A updates

Biogen Inc. (BIIB) is up 4.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to Biogen’s April 29 first-quarter results that beat expectations, alongside upbeat commercial momentum in several growth products and fresh updates on late-stage programs. Investors also seem to be weighing strategic steps to broaden Biogen’s growth profile, including its pending Apellis transaction, even as 2026 EPS guidance was lowered for business-development related charges.

Details:

Biogen reported Q1 2026 revenue of $2.478 billion and non-GAAP diluted EPS of $3.57, alongside year-over-year growth in its “growth products” portfolio.

The company highlighted LEQEMBI global in-market sales of $168 million (with U.S. in-market sales of $86 million) and SKYCLARYS revenue of $151 million, both cited as driven by demand growth and continued sequential progress.

Biogen disclosed that the FDA approved the SPINRAZA High Dose Regimen, which it framed as an important lifecycle milestone for the SMA franchise.

Biogen updated full-year 2026 non-GAAP EPS guidance to $14.25–$15.25 (excluding Apellis) to reflect acquired IPR&D charges tied to ongoing business development, while reiterating plans to provide updated guidance inclusive of Apellis after the deal closes.

Sources:

SEC, Biogen Investor Relations, MarketBeat

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$BIIB Insider Trading Activity

$BIIB insiders have traded $BIIB stock on the open market 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $BIIB stock by insiders over the last 6 months:

PRIYA SINGHAL (Head of Development) has made 0 purchases and 2 sales selling 3,408 shares for an estimated $665,664.
NICOLE MURPHY (Head of Pharm Ops and Tech) purchased 3 shares for an estimated $585

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.

EARLY ACCESS

Receive BIIB Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$BIIB Hedge Fund Activity

We have seen 462 institutional investors add shares of $BIIB stock to their portfolio, and 392 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC added 8,138,103 shares (+632.0%) to their portfolio in Q4 2025, for an estimated $1,432,224,746
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 4,365,462 shares (-75.8%) from their portfolio in Q4 2025, for an estimated $768,277,657
BOSTON PARTNERS added 1,720,595 shares (+inf%) to their portfolio in Q4 2025, for an estimated $302,807,514
PACER ADVISORS, INC. removed 1,451,249 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $255,405,311
POINT72 ASSET MANAGEMENT, L.P. removed 1,059,709 shares (-27.4%) from their portfolio in Q4 2025, for an estimated $186,498,186
FRED ALGER MANAGEMENT, LLC added 796,735 shares (+39074.8%) to their portfolio in Q4 2025, for an estimated $140,217,392
INVESCO LTD. removed 762,686 shares (-31.5%) from their portfolio in Q4 2025, for an estimated $134,225,109

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

$BIIB Congressional Stock Trading

Members of Congress have traded $BIIB stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $BIIB stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 01/30.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API.

$BIIB Analyst Ratings

Wall Street analysts have issued reports on $BIIB in the last several months. We have seen 2 firms issue buy ratings on the stock, and 1 firms issue sell ratings.

Here are some recent analyst ratings:

Oppenheimer issued a "Outperform" rating on 01/30/2026
HSBC issued a "Reduce" rating on 12/10/2025
Stifel issued a "Buy" rating on 11/06/2025

To track analyst ratings and price targets for $BIIB, check out Quiver Quantitative's $BIIB forecast page.

$BIIB Price Targets

Multiple analysts have issued price targets for $BIIB recently. We have seen 19 analysts offer price targets for $BIIB in the last 6 months, with a median target of $214.0.

Here are some recent targets:

Michael Yee from UBS set a target price of $225.0 on 04/22/2026
Mohit Bansal from Wells Fargo set a target price of $250.0 on 04/20/2026
David Amsellem from Piper Sandler set a target price of $214.0 on 04/14/2026
Srikripa Devarakonda from Truist Securities set a target price of $189.0 on 04/13/2026
Geoff Meacham from Citigroup set a target price of $190.0 on 04/13/2026
Matthew Harrison from Morgan Stanley set a target price of $200.0 on 04/10/2026
Andrew S. Fein from HC Wainwright & Co. set a target price of $237.0 on 04/02/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.